Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
huCART-meso cells in Pancreatic Cancer
NCT03323944Phase 1Terminated
- Sponsor
- University of Pennsylvania
- Start
- Sep 2017
- Primary completion
- Feb 2025
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of huCART-meso cells in pancreatic adenocarcinoma (PDAC) (5 cohorts), sponsored by University of Pennsylvania. Primary endpoint: Number of study subjects with treatment-related adverse events at 2 years. Started Sep 2017; status: terminated.
02
Drugs
huCART-meso cells
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03323944.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03323944.